Nivolumab and relatlimab

(Opdualag®)

Opdualag®

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (intravenous; 240 mg of nivolumab and 80 mg of relatlimab per 20 mL [12 mg and 4 mg per mL] in a single-dose vial)
Drug ClassProgrammed death receptor-1 (PD-1) blocking antibodies and lymphocyte activation gene-3 (LAG-3) blocking antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Nivolumab and relatlimab (Opdualag) are indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. They exhibit similar progression-free survival (PFS) and overall response rate (ORR) compared to the combination of ipilimumab and nivolumab but tends to have a better safety profile concerning severe treatment-related adverse events.
  • Two studies were reviewed to gather information about Opdualag's effectiveness and safety.
  • The studies suggest that PD-(L)1/BRAF/MEK inhibitors may be superior in terms of both PFS and ORR, potentially positioning these regimens above Opdualag in BRAF-mutant patient populations. However, direct comparison data between Opdualag and BRAF/MEK inhibitors were not explicitly provided.
  • In comparing other immune checkpoint inhibitor (ICI) regimens, certain combinations involving nivolumab had higher overall survival rates than others. Meanwhile, pembrolizumab at a dose of 10 mg/kg was noted for its high efficiency as well as an improved safety profile over other ICIs, including those containing nivolumab.
  • No detailed breakdowns by demographic subgroups such as age beyond the stipulation that treatments included patients aged 12 years or older were given in these studies. This suggests a need for further research into subgroup considerations.
  • Overall, evidence suggests that Opdualag is competitive amongst various options available today due to its balance between efficacy against advanced melanoma alongside fewer reported instances regarding serious side effects from usage compared with alternatives like ipilimumab/nivolumab.

Product Monograph / Prescribing Information

Document TitleYearSource
Opdualag (nivolumab and relatlimab) Prescribing Information. 2022Bristol-Myers Squibb Company Princeton, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Systemic Therapy for Melanoma: ASCO Guideline Update.2023Journal Of Clinical Oncology